CanAg® CEA EIA

Carcinoembryonic antigen (CEA) is a glycoprotein, which was first identified in patients with colon carcinoma and in epithelial tumors of endodermal origin (gastrointestinal tract) by Gold and Freedman1. The CEA molecule is quite heterogeneous due to the carbohydrate contents (50 % - 60 %). It is soluble in perchloric acid and has a molecular weight of about 175.000 to 200.000 Daltons2. Immunological and genetic characterization of CEA has identified a family of CEA-like molecules sharing common antigenic determinants. The most relevant CEA-like molecule is NCA (nonspecific cross-reacting antigen) synthesized both by normal and pathological tissues. The problem of cross-reacting CEA-like molecules when assaying CEA is possible to overcome by the use of monoclonal antibodies. The CEA EIA is based on two mouse monoclonal antibodies against the Gold epitopes IV and V3, 4.

CEA is secreted from tumor cells and is a widely used serological marker of gastrointestinal carcinomas, lung cancer, and breast cancer. In colorectal cancer, the clinical use of CEA testing for monitoring response to therapy and for documenting progressive disease is well established5, 6. CEA may also be present in benign gastrointestinal inflammatory diseases or in hepatobiliary diseases. These observations make it necessary to emphasize that the CEA assay should not be used as a cancer-screening test.

 

References

  1. Gold P. and Freedman S. O. (1965) Specific carcinoembryonic antigens of the human digestive system. J. Exp Med 122: 467-481.

  2. Thompson J.A. and Zimmerman W. (1988) The carcinoembryonic antigen gene family: Structure, expression and evolution. Tumor Biol,; 9: 63-83.

  3. Börmer, O.P. (1992) Thesis “Immunoassays for Carcinoembryonic antigen, Specificity and Interferences”, ISBN 82-7633-014-2.

  4. Hammarström S. et al. (1989) Antigenic sites in carcinoembryonic antigen. Cancer Res 49: 4852-4858.

  5. Tumor Marker Expert Panel, ASCO (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin Oncol; 14:2843-2877.

  6. Fleisher M. et al. (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. National Academy of Clinical Biochemistry 15: 26-29.

CE marked
CanAg CEA EIA

Product number 401-10

For 96 determinations
Contact sales for information and inquiries
Please contact your local Fujirebio representative for the availability of this product in your country.
  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.